Will Novo's LEADER Trial Move GLP-1 To The Diabetes Front Line?
This article was originally published in Scrip
Executive Summary
Novo Nordisk AS has an impressive victory with a benefit demonstrated in the LEADER cardiovascular outcomes study of its GLP-1 agonist Victoza (liraglutide) in high-risk type 2 diabetes, but the real test could be whether the magnitude of benefit is big enough to shift practice and expand use beyond the class's tiny base.
You may also be interested in...
Q1 Earnings In Brief: Celgene, Alkermes, Novo Nordisk, Acorda, Alexion
First quarter earnings are in full swing. Here is a look at what some companies are saying to analysts during their quarterly calls. Celgene talks up Revlimid; Alkermes bullish on Aristada launch; Victoza market share threatened by Trulicity; Acorda plans for Phase III in post-stroke; Soliris still backbone at Alexion.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.